Dividend Distribution - The company plans to distribute a cash dividend of 0.5 RMB per 10 shares to all shareholders, based on a total of 510,657,000 shares[4]. - The board of directors has approved the profit distribution plan, which does not include any bonus shares or capital reserve transfers[4]. - The company’s cash dividend policy was executed in accordance with its articles of association, ensuring the protection of minority shareholders' rights[144]. Financial Performance - The company's operating revenue for 2022 was ¥1,019,176,339.15, representing a 24.65% increase compared to ¥817,640,826.02 in 2021[6]. - The net profit attributable to shareholders for 2022 was ¥105,945,825.56, a 13.60% increase from ¥93,258,956.07 in 2021[6]. - The net cash flow from operating activities surged by 510.48% to ¥72,369,956.27 in 2022, compared to ¥11,854,642.44 in 2021[6]. - The basic earnings per share for 2022 was ¥0.2075, up 13.64% from ¥0.1826 in 2021[6]. - Total assets at the end of 2022 reached ¥2,586,568,848.41, a 9.97% increase from ¥2,352,093,709.48 at the end of 2021[6]. - The net assets attributable to shareholders increased by 6.24% to ¥1,715,389,713.37 at the end of 2022, compared to ¥1,614,577,062.37 at the end of 2021[6]. - The company reported a significant increase in government subsidies, totaling ¥75,662,519.83 in 2022, compared to ¥32,638,552.20 in 2021[8]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY in 2022, representing a year-on-year growth of 15%[119]. Market Position and Strategy - The company is positioned in a growing market driven by national policy support and increasing health awareness, indicating a favorable outlook for the traditional Chinese medicine sector[30]. - The company faces intensified competition and regulatory scrutiny in the pharmaceutical industry, which may impact its market positioning[32]. - The company is focusing on high-quality development in the traditional Chinese medicine sector, aligning with national strategic initiatives[31]. - The company is actively pursuing international market expansion and has acquired Hong Kong Fozi Pharmaceutical Co., Ltd. to strengthen its overseas presence[39]. - The company aims to create over 1 billion market segments in regions such as Shanghai, Jiangsu, Zhejiang, Guangdong, and Sichuan-Chongqing, as well as international markets[85]. - The company is expanding into five major markets, including consolidating its base in Shaanxi and Gansu, and developing the North China market with strategic partners[86]. Research and Development - The company is focused on innovation-driven development, increasing R&D investment to enhance its core competitiveness in traditional Chinese medicine[35]. - R&D investment amounted to ¥23,555,522.20 in 2022, an increase of 21.69% compared to ¥19,357,135.92 in 2021[66]. - The number of R&D personnel increased to 189 in 2022, up 15.24% from 164 in 2021, with a proportion of 15.99% of total employees[67]. - New product development initiatives are underway, with an investment of 100 million CNY allocated for R&D in traditional Chinese medicine[119]. - The company is actively developing new products and enhancing its R&D capabilities through collaboration with research institutions[65]. Corporate Governance - The company emphasizes the importance of a modern corporate governance structure to ensure compliance with regulations and enhance operational transparency[101]. - The board of directors operates under a structured governance framework, including specialized committees for strategy, audit, compensation, and nomination[105]. - The company has established an audit committee to oversee internal and external audits, ensuring compliance and accuracy of financial information[105]. - The company has maintained a stable operational structure despite the changes in leadership, indicating a focus on continuity in its strategic direction[113]. - The company has a performance-based remuneration system for its directors and senior management[128]. Social Responsibility - The company actively engages in social responsibility initiatives, including poverty alleviation and community health lectures[161]. - The company donated medical supplies and materials worth 12 million yuan to various medical institutions and schools through the Red Cross Society[160]. - The company has implemented a change in accounting estimates for bad debt provisions, reducing the expected credit loss rate for non-overdue receivables from 2.59% to 0%[167]. - The company has strengthened its environmental responsibility awareness and is committed to building a green factory[160]. Internal Control and Compliance - The company has established 250 management systems, with 82 new or revised systems during the reporting period, enhancing internal control measures[146]. - The company reported no significant internal control deficiencies during the reporting period[147]. - The company maintained effective internal control over financial reporting as of December 31, 2022, according to the internal control audit report[149]. - The internal control audit report received a standard unqualified opinion, indicating no major deficiencies[150]. Employee Management - The total number of employees at the end of the reporting period was 1,404, including 1,096 at the parent company and 308 at major subsidiaries[139]. - The company has a training center that focuses on improving employees' professional skills and overall quality through various training programs[141]. - The company has maintained a harmonious labor relationship by ensuring employee rights and providing welfare benefits[156]. Financial Audits and Reporting - The audit firm Lianda CPA was appointed for the 2022 financial audit, with a fee of 390,000 RMB, marking the first year of service[171]. - The company conducted regular communications with the annual audit firm regarding the audit of the previous year's financial statements[136]. - The board of directors held a total of 7 meetings during the reporting period, with decisions disclosed on various dates[131].

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20140710 | --- | --- | --- | |---------------------|------------------------------|--------------------------------------------------| | | ■ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 宏源证券研究所：赵佳、王晓锋 | | | 人员名称 | | | | 时间 | 2014 年 7 月 10 | 日 下午 15：00——16：00 | | 地点 | 公司三楼会议室 | | | 上市公司接待 | | | | 人员姓名 | 董事长：李云鹏 | 证券部：李莹 | | 投资者关系活动 | | 此次调研活动以会谈交流形式进行，主要内容如下： | | 主要内容介绍 | | 1、问：政府对公司搬入新区的 ...

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 | --- | --- | --- | |-------------------------|-------------------------|---------------------------------------------------------| | | | | | | ■ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | | | 西南证券何治力、中国人寿资产丁天宇、中银基金刘潇、东海 | | 参与单位名称及 人员名称 | | 证券杨莹、中海基金郑辰、野风资产于波 、上海汇利资产叶 | | | | 丽、长江证券刘锐、上投摩根罗会礼 | | 时间 | 2015 年 8 月 12 | 日 上午 9：30——11：00 | | 地点 | 公司三楼会议室 | | | 上市公司接待 | | | | 人员姓名 | | 董事长李云鹏、董事会秘书吕芝瑛、证 ...

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20150506 | --- | --- | --- | |----------------|-----------------------------|----------------------------------------------------------| | | | | | | ■ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □路演活动 | | 类别 | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | | 银河基金、财通证券、深圳尊道投资、中投证券、华创证券、创 | | 人员名称 | 金合信基金 | | | 时间 | 2015 年 5 月 7 日 | 下午 15：30——17：00 | | 地点 | 公司三楼会议室 | | | 上市公司接待 | | 董事长李云鹏、总经理孙裕、董事会秘书吕芝瑛、证券部部长 | | 人员姓名 | 李文梅、证券事务代表安文婷 | | | 投资者关系活动 | ...

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20151116 | --- | --- | --- | |-----------------------|--------------------------|------------------------------------------------------| | | | | | | ■ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 华龙证券孟洁 | | | 人员名称 | | | | 时间 | 2015 年 11 月 16 | 日 下午 14:00——15：00 | | 地点 | 公司三楼会议室 | | | 上市公司接待 人员姓名 | | 董事会秘书吕芝瑛、证券事务代表安文婷 | | 投资者关系活动 | | 此次调研活动主要以会谈交流形式进行，会谈主要内容 | | 主要内容介绍 | 如下： | | | | 1 | ...

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20150302 | --- | --- | --- | |----------------|------------------------------|------------------------------------------------| | | | | | | ■ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □路演活动 | | 类别 | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 中国中投证券：池陈森 | | | 人员名称 | | | | 时间 | 2015 年 3 月 2 日 | 下午 2：00——3：10 | | 地点 | 公司三楼会议室 | | | | 总经理：孙裕 | | | 上市公司接待人 | 董事会秘书：吕芝瑛 | | | 员姓名 | 证劵部部长：李文梅 | | | 投资者关系活动 | | 此次调研活动以会谈交流形式进行，主要内容如下： | | 主要内容介绍 | 1 ...

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20150624 | --- | --- | --- | |---------------------|------------------------------|--------------------------------------------------------| | | | | | | ■ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | | 华创证券张伟光、泰达宏利基金庞文杰、新华基金吴洋、东方 | | 人员名称 | 证券张韡、中国东方资产伍一支 | | | | | | | 时间 | 2015 年 6 月 24 | 日 上午 9： 00——11：00 | | 地点 | 公司三楼会议室 | | | 上市公司接待 | | 总经理孙裕、董事会秘书吕芝瑛、证券事务代表安文婷 | | 人员姓名 | | | | 投资者关系 ...

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20160726 | --- | --- | --- | |-------------------------|-------------------------|--------------------------------------------------------| | | | | | | ■ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | | | 招商证券李点典、民生证券刘淼、六禾投资陈信余、光大资管 | | 参与单位名称及 人员名称 | | 王晶、朱雀投资傅鹏、诺安基金杜佐远、华夏基金李彦、华融 | | | 证券金春萍 | | | 时间 | 2016 年 7 月 26 | 日 | | 地点 | 公司三楼会议室 | | | 上市公司接待 | | 董事长李云鹏、总经理孙裕、董事会秘书吕芝瑛、证券事务代 | | 人员姓名 | 表安文婷 | ...

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20161027 | --- | --- | --- | |-----------------------|--------------------------|--------------------------------------------------------| | | | | | | ■ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □路演活动 | | 类别 | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | | 浙商证券张海涛、中投证券孙明达、国联安基金焦阳、信达澳 | | 人员名称 | 银杨珂、万家基金杨珂 | | | 时间 | 2016 年 10 月 27 | 日 下午 | | 地点 | 公司三楼会议室 | | | | | | | 上市公司接待 人员姓名 | | 董事会秘书吕芝瑛、证券事务代表安文婷 | | 投资者关系活动 | | 此次调研活动主要以会谈交流形式进行，会谈主要内容 ...